MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome
This study has been completed.
Sponsor:
Merck
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00543595
First received: October 5, 2007
Last updated: October 12, 2007
Last verified: October 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 2 Metabolic Syndrome |
Drug: MK0916 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Merck:
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Have Type 2 Diabetes
- 18 to 65 years of age
Exclusion Criteria:
- History of Type 1 Diabetes Mellitus
- Have been treated with insulin in the past 8 weeks
- On a weight loss program and have ongoing weight loss
- Taking weight loss medication
- Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
- Have taken another investigational drug in the last 8 weeks
- Have active liver disease
- Have a history of major surgery involving gastric or intestinal bypass
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00543595 History of Changes |
| Other Study ID Numbers: | 2007_643 |
| Study First Received: | October 5, 2007 |
| Last Updated: | October 12, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Metabolic Syndrome X Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Insulin Resistance Hyperinsulinism |
ClinicalTrials.gov processed this record on May 21, 2013